BioGaia AB (publ)
Research BioGaia AB (publ) (BIOG-B) on Bullrun: valuation model: 2.9% overvalued, market cap SEK 11.68B, P/E 33.7, dividend yield 3.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOG-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Valuation signal2.9% overvalued
- Market capSEK 11.68B
- P/E33.7
- Dividend yield3.5%
- Financial periodQ2 2026
- RevenueSEK 440.86M
- Net incomeSEK 103.16M
- Free cash flowSEK 38.64M
- Gross margin72.8%
Valuation Snapshot
Bullrun's latest valuation model marks BioGaia AB (publ) as 2.9% overvalued; latest market cap is SEK 11.68B; P/E is 33.7; dividend yield is 3.5%.
Peer valuation comparison
Latest P/E is 33.67x versus a Healthcare sector median of 24.46x (37.7% above).
Latest dividend yield is 3.47% versus a Healthcare sector median of 2.11% (64.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 1.54B | SEK 332.76M | n/a | 73.4% | n/a | SEK 801.31M | n/a | SEK 1.31B |
| FY2024 | SEK 1.42B | SEK 351.39M | n/a | 72.4% | n/a | SEK 1.22B | n/a | SEK 1.72B |
| FY2023 | SEK 1.30B | SEK 365.36M | n/a | 73.3% | n/a | SEK 1.54B | n/a | n/a |
| FY2022 | SEK 1.10B | SEK 373.77M | SEK 301.03M | 72.6% | 37 | SEK 1.49B | n/a | SEK 1.97B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | SEK 11.68B | 33.7 | 1.4% | 1.64 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.64 SEK, yield 3.5%.
| Year | Dividends/share |
|---|---|
| FY2022 | 2.98 SEK |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is BioGaia AB (publ) overvalued or undervalued?
Bullrun's valuation model currently marks BioGaia AB (publ) as 2.9% overvalued.
What is BioGaia AB (publ)'s market cap?
BioGaia AB (publ)'s market capitalization is SEK 11.68B.
What is BioGaia AB (publ)'s P/E ratio?
BioGaia AB (publ)'s price-to-earnings (P/E) ratio is 33.7.
Does BioGaia AB (publ) pay a dividend?
BioGaia AB (publ) has a dividend yield of 3.5%.
What does BioGaia AB (publ) do?
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula.